Freenome’s comprehensive multiomics and multi-feature computational approach provides insights for therapy development and patient efficacy
SOUTH SAN FRANCISCO, Dec. 12, 2022 — Freenome, a privately held biotech company, presented research on Saturday at the American Society of Hematology (ASH) Annual Meeting in New Orleans.
Freenome’s multiomics platform allows researchers to look across multiple levels of biology to form a comprehensive analysis of signals seen in blood, capturing both tumor-derived and non-tumor-derived biomarkers including those from the immune system.
Freenome and ADC Therapeutics have been applying this platform to investigate biological signatures associated with response to loncastuximab tesirine (lonca), a CD-19-directed antibody drug conjugate developed by ADC Therapeutics that is indicated for the treatment of adult patients with relapsed/refractory (r/r) diffuse large B-cell lymphoma (DLBCL) after ≥2 prior lines of therapy.
The initial results are part of a larger ongoing collaboration between the companies. The findings presented at ASH show promise in identifying biomarkers associated with response to lonca and also suggested mechanisms of resistance seen in non-responders, which may inform future drug combination research. In addition, the researchers demonstrated that they could combine the cfDNA profiling results with data from routine clinical testing to make better predictions of patient-specific response.
“Freenome’s unique multiomics platform shows potential to identify biomarkers associated with both response and resistance to treatment with lonca,” said Patrick van Berkel, Ph.D. and chief scientific officer of ADC Therapeutics. “We look forward to further exploration of these findings to determine their significance for healthcare providers trying to identify the most appropriate treatments for patients with DLBCL.”
“ADC Therapeutics is a leader in the field of antibody-drug conjugates,” said Mike Nolan (Freenome CEO). “Together, we are demonstrating how our multiomics platform can be applied to heme malignancies in order to contribute to the early detection and early intervention of cancer.”